<DOC>
	<DOCNO>NCT02016690</DOCNO>
	<brief_summary>This post marketing observational study ( PMOS ) conduct Japan 2013-2014 2014-2015 Respiratory Syncytial Virus ( RSV ) season assess safety effectiveness palivizumab prevention serious low respiratory tract infection cause RSV participant 24 month age , immunocompromised medical condition ( e.g. , combined immunodeficiency disease , antibody deficiency , type immunodeficiency ; HIV infection ; recover organ bone marrow transplantation ; chemotherapy ; high-dose corticosteroid therapy ; immunosuppressant ) Down syndrome .</brief_summary>
	<brief_title>Synagis® Liquid 50mg , 100mg Intramuscular Injection Special Investigation Immunocompromised Children With Synagis®</brief_title>
	<detailed_description>Palivizumab prescribe accord local label independently decision enroll participant study . Palivizumab administer monthly throughout Respiratory Syncytial Virus ( RSV ) infection season via intramuscular injection dose 15 mg/kg body weight . Survey form collected observation period . The number adverse event frequency hospitalization due RSV infection survey participant assessed evaluate safety effectiveness palivizumab .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>1 . Availability parent legal guardian capable willing give write informed consent his/her newborn , infant young child participate study 2 . Participants receive palivizumab prevention serious low respiratory tract disease cause RSV infection 3 . Newborns , infant , young child 24 month age immunocompromised medical condition : combined immunodeficiency , ( severe combine immunodeficiency , Xlinked hyperimmunoglobulin M ( IgM ) syndrome , etc . ) , antibody deficiency ( Xlinked agammaglobulinemia , common variable immunodeficiency , nonXlinked hyperIgM syndrome , etc . ) immunodeficiency ( WiskottAldrich syndrome , etc . ) acquire T cell dysfunction ( human immunodeficiency virus ( HIV ) infection etc . ) history past organ transplantation history past bone marrow transplantation receive immunosuppressive chemotherapy receive systemic highdose corticosteroid therapy ( prednisone equivalent ≥ 0.5 mg/kg/every day , inhaler topical use ) , receive immunosuppressive therapy ( azathioprine , methotrexate , mizoribine , mycophenolate mofetil , cyclophosphamide , cyclosporine , tacrolimus , cytokine inhibitor , etc . ) receive biologics ( include cytokine inhibitor ) Others ( nephrotic syndrome , chronic peritoneal dialysis , hemodialysis ) 4 . Newborns , infant , young child age 24 month Down syndrome without current hemodynamically significant Congenital Heart Disease . The participant must experience persistent respiratory symptom regular outpatient treatment due respiratory tract infection prior current RSV season . Exclusion criterion : 1 . Participants include Contraindications section package insert 2 . Participants know hypersensitivity ingredient palivizumab 3 . Participants know positive RSV infection hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prevention severe RSV infection</keyword>
	<keyword>Respiratory syncytial virus ( RSV ) infection</keyword>
	<keyword>Down Syndrome</keyword>
	<keyword>Immunocompromised</keyword>
	<keyword>Effectiveness palivizumab</keyword>
</DOC>